ITEMS IN AFP WITH KEYWORD:
S.O. is a 47-year-old woman who presents to your office for a well-woman visit. She is healthy, takes no medications, and has no health concerns. She has never been diagnosed with breast cancer, nor have any of her first-degree relatives. Her digital mammography two years ago was negative, and she a...
Based on the initial round of screening in this randomized trial, it appears that more patients complete fecal immunochemical testing than colonography or colonoscopy. Using the most conservative estimate, the yields of advanced adenomas and advanced neoplasms are similar.
In keeping with the principles of the Choosing Wisely campaign, physicians and patients would do well to avoid the pitfalls of overscreening and wait for results that promise more hope than hype.
An overview of the recent results from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and implications for clinical practice and public health.
Decisions about cancer screening in older patients should be individualized, taking into account life expectancy, potential benefits vs. harms, and patient preferences. Get suggestions on how to incorporate current guidelines into daily practice.
Apr 15, 2016 Issue
Screening for Breast Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
Practical strategies can help family physicians and women in their 40s make more informed decisions about breast cancer screening.
The American Cancer Society (ACS) organized an interdisciplinary guideline development group to review the available evidence on breast cancer mortality, quality of life, life expectancy, false-positive findings, overdiagnosis, and overtreatment, and to update their 2003 guideline on breast cancer screening in average-risk women.
Before primary care physicians consider reintroducing the PSA test, they must have proof that it improves outcomes. The task will be to show in a future randomized study whether any PSA screening algorithm can improve survival or quality of life compared with what is now the standard of care—no routine screening.
Studies show no deaths were prevented and 1 in 5 underwent a prostate biopsy for a false-positive test. Read more.